Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

See our complete portfolio of awards below.

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
Stanford University Dr. Matthew H Porteus Late Stage Preclinical Projects Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease $4,849,363
Cellerant Therapeutics, Inc. Swapna Panuganti Late Stage Preclinical Projects Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia $6,863,755
Cellular Biomedicine Group, Inc. Jack J. Wang Late Stage Preclinical Projects Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis $1,200,000
Stanford University Dr. Gary Steinberg Late Stage Preclinical Projects Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke $5,300,000
University of California, San Diego Dr. Stephanie Cherqui Late Stage Preclinical Projects Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis $5,273,189
University of California, Los Angeles Dr. Sophie X Deng Late Stage Preclinical Projects Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy $4,244,211
ViaCyte, Inc. Dr. Tim Kieffer Late Stage Preclinical Projects Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes $3,544,721
University of California, San Francisco Dr Jennifer M Puck Late Stage Preclinical Projects Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) $4,268,865
Angiocrine Bioscience, Inc. Dr. Paul W Finnegan Late Stage Preclinical Projects Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy $3,797,117
Calibr Peter G Schultz Late Stage Preclinical Projects Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis $1,667,832
Cedars-Sinai Medical Center Shaomei Wang Late Stage Preclinical Projects IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa $4,954,514
Calibr Peter G Schultz Preclinical Development Awards Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis $2,306,703
Scripps Health Dr. Darryl D. D’Lima Preclinical Development Awards Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects $7,660,211
University of California, Davis Dr. Roslyn Rivkah Isseroff Preclinical Development Awards Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds $4,620,144
University of California, Irvine Dr. Leslie M Thompson Preclinical Development Awards A hNSC Development Candidate for Huntington’s Disease $4,951,623
Stanford University Dr. Matthew H Porteus Preclinical Development Awards Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 $874,877
University of California, Davis Dr. Diana L. Farmer Preclinical Development Awards Placental Stem Cells for the In Utero Treatment of Spina Bifida $2,182,146
Salk Institute for Biological Studies Dr. David R Schubert Preclinical Development Awards Human Stem-Cell Based Development of a Potent Alzheimer’s Drug Candidate $1,664,885
ViaCyte, Inc. Howard Foyt Accelerated Development Pathway I Clinical Development of a Cell Therapy for Diabetes $8,783,852
University of California, San Diego Dr. Catriona Jamieson Alpha Stem Cell Clinics Alpha Stem Cell Clinic for the Development of Regenerative Therapies $8,679,137
University of California, Los Angeles John S. Adams Alpha Stem Cell Clinics UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium $8,680,000
City of Hope, Beckman Research Institute Prof. John A. Zaia Alpha Stem Cell Clinics The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. $8,416,531
University of California, Davis Dr. J. Kent Leach Tools and Technologies III Multi-modal technology for non-destructive characterization of bioengineered tissues $1,574,151
University of Southern California Dr. Qilong Ying Tools and Technologies III Embryonic stem cell-based generation of rat models for assessing human cellular therapies $1,326,979
Stanford University Sarah Heilshorn Tools and Technologies III Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System $1,347,767
Stanford University Dr. James C. Dunn Dr. Tools and Technologies III Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $772,098
Cedars-Sinai Medical Center Professor Clive Niels Svendsen Disease Team Therapy Planning I Stem Cells Secreting GDNF for the Treatment of ALS $63,487